Rubius Therapeutics, Inc. - 10-Q filing on 2021-05-10

Investments and Fair Value of Financial Assets and Liabilities (Tables)

3 Months Ended

Mar. 31, 2021

Investments and Fair Value of Financial Assets and Liabilities

Schedule of investments by security type

Investments by security type consisted of the following (in thousands):


	March 31, 2021
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Credit Losses		Fair Value
U.S. treasury bills and notes (due within one year)	$	42,557	$	7	$	—	$	—	$	42,564
	$	42,557	$	7	$	—	$	—	$	42,564


	December 31, 2020
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Credit Losses		Fair Value
U.S. treasury bills and notes (due within one year)	$	85,118	$	6	$	(2)	$	—	$	85,122
	$	85,118	$	6	$	(2)	$	—	$	85,122

Schedule of financial assets and liabilities measured at fair value on a recurring basis

The following tables present the Company’s fair value hierarchy for its assets and liabilities, which are measured at fair value on a recurring basis (in thousands):


	Fair value measurements at March 31, 2021 using:

	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents:
Money market funds	$	275,347	$	—	$	—	$	275,347
Investments:
U.S. treasury bills and notes		—		42,564		—		42,564
	$	275,347	$	42,564	$	—	$	317,911


	Fair value measurements at December 31, 2020 using:

	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents:
Money market funds	$	88,814	$	—	$	—	$	88,814
Investments:
U.S. treasury bills and notes		—		85,122		—		85,122
	$	88,814	$	85,122	$	—	$	173,936